Sign in
Taking people in PortugalPhase 2/3

Tests telisotuzumab adizutecan with osimertinib for EGFR-mutated lung cancer

Tests a new drug combined with osimertinib in adults with EGFR-mutated non-small cell lung cancer.

Key facts

Who runs it
AbbVie Deutschland GmbH & Co. KG
Where
Braga and Porto, PortugalSee the 3 sitesAlso in 3 other countries, 14 sites
Registry title
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Status
Recruiting
Phase
Phase 2/3
People taking part
50 people, planned
Started
18 Sept 2025
Expected to end
29 Dec 2031
Type of study
Interventional
Record updated
14 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-squamous non-small cell lung cancer that has an EGFR mutation, is advanced or has spread, and cannot be removed by surgery. It tests telisotuzumab adizutecan with osimertinib as first treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Locally advanced and unresectable, or metastatic EGFR-mutated non-squamous non-small cell lung cancer, with at least one measurable tumour that has not been irradiated
Earlier treatment
Side effects from earlier cancer treatment must have settled to Grade 1 or the starting level, apart from hair loss or nerve damage up to Grade 2
Biomarker or test result
Tumour tissue must be given for c-Met IHC testing before randomization

Main reasons for not taking part

  • History of interstitial lung disease or pneumonitis treated with steroids
  • History of pulmonary fibrosis or organizing pneumonia
  • Another cancer, apart from a few limited exceptions
  • Leptomeningeal disease
  • Spinal cord compression not definitively treated with surgery or radiation

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 during the screening period and prior to dosing of study treatment on Cycle 1 Day 1
  • All participants must consent to provide recently obtained FFPE tumor tissue (ideally collected during or after locally advanced or metastatic diagnosis) or archived tissue during screening for c-Met IHC testing and study stratification. c-Met IHC results are required prior to randomization
  • Participants must have at least one non-irradiated measurable disease per RECIST version 1.1. If only one measurable lesion exists, it is acceptable to be used (as a target lesion) as long as it has not been previously irradiated and as long as it has not been biopsied within 14 days of the baseline tumor assessment scans
  • Any toxicities from prior systemic anti-cancer therapy must have resolved to CTCAE Grade 1 or baseline level (except for alopecia [any grade] or Grade ≤ 2 peripheral neuropathy)
  • Participants should not have any major, life-threatening conditions and life expectancy as determined by the investigator should be at least 3 months

Who cannot take part

  • History of interstitial lung disease (ILD), pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest CT scan
  • History of any malignancy other than disease under study except for a. Malignancy treated with curative intent and with no known active disease present for 2 years before the first dose of study treatment and felt to be at low risk for recurrence by investigator. b. Successfully treated nonmelanoma skin cancer. c. Localized carcinoma in situ of the cervix. d. Breast Cancer; lobular carcinoma in situ or ductal carcinoma in situ that is considered completely cured
  • Participants has leptomeningeal disease, or subject has spinal cord compression not definitively treated with surgery or radiation
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis

Where in Portugal

Also in 3 other countries, 14 sites

  • CCAB Centro Clinico Academico Braga AssociacaoBraga, PortugalTaking people
  • Hospital CUF Porto S.A.Porto, PortugalTaking people
  • Unidade Local De Saude De Santo Antonio E.P.E.Porto, PortugalTaking people

About the trial

What the trial wants to find out

Phase 2: - To evaluate the safety and tolerability of telisotuzumab adizutecan in combination with osimertinib. - To optimize and select the RP3D of telisotuzumab adizutecan in combination with osimertinib. - To evaluate the efficacy as measured by ORR of telisotuzumab adizutecan in combination with osimertinib. Phase 3: To demonstrate the superiority of telisotuzumab adizutecan in combination with osimertinib over standard of care in terms of efficacy measured by PFS based on BICR assessment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Plain-language title
Tests telisotuzumab adizutecan with osimertinib for EGFR-mutated lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
14 April 2026